Dave Mihalovic
Prevent Disease
September 23, 2010
The Public Health Agency of Canada has once again given their seal of approval for the injection of a dangerous cocktail of toxic chemicals they call a trivalent vaccine. The 2010/11 recipients of AstraZeneca’s FLUMIST will be exposed to several strains of live viruses including H1N1 and H3N2. The vaccine also contains MSG and other known neurotoxins and immunotoxins.
Similar to last year’s Arepanrix Vaccine, FLUMIST was approved without evaluating its safety and effectiveness on a single Canadian.
The vaccines are especially being promoted for children since the nasal spray vaccine can be marketed as less invasive due its intranasal delivery that does not require needles. Ontario’s chief medical officer of health said a non-injectable vaccine is an “attractive option.” The product has been on the U.S. market for the last seven years.
AstraZeneca Canada is currently ensuring that all Canadian pharmacies are making preparations to stock the vaccine this fall. The influenza vaccine will be one of several vaccines to be offered on the Canadian market.
On August 26, 2010, Health Canada issued a Notice of Decision to AstraZeneca Canada for the FLUMIST vaccine.
The FLUMIST Trivalent vaccine product information:
Three Live Viruses:
- Influenza Virus Type A (H1N1);
- Influenza Virus Type A (H3N2); and
- Influenza Virus Type B
Route of Administration:
Intranasal Spray
Dosage Strength:
0.2 mL
Clinically Relevant Nonmedicinal Ingredients
- Gelatin hydrolysate (porcine Type A)
- sucrose
- arginine
- gentamicin
Additional Toxic Ingredients:
- Monobasic potassium phosphate: Immunotoxin
- Arginine hydrochloride: Toxic to lungs and mucous membranes
- Monosodium glutamate: Neurotoxin, Excitotoxin
- Gentamicin: Nephrotoxic
Discussion
There are currently NO clinical trials or results which have validated the long-term safety and efficacy of the FLUMIST vaccine. Regulatory health agencies are refusing to acknowledge this fact or the nature of toxicity levels associated with the FLUMIST and its ingredients. The well documented toxicity evidence for each ingredient presented above are simply ignored.
If you’ll notice, most of the ingredients that are considered non-clinically relevant excipients are ALL TOXIC and yet still injected in every person that receives the vaccine.
No Pharmacokinetic, Carcinogenic or Fertility Studies
One of the most critical elements which defines the toxicity potential of any vaccine are its pharmacokinetic properties. AstraZeneca and Medimmune do not consider the study, analysis or evaluation of the pharmacokinetic properties of any vaccine ingredients or excipients including FLUMIST. This means that the bodily absorption, distribution, metabolism and excretion of ingredients within the vaccine are not known or even considered in safety assessments.
FLUMIST has not been evaluated for its carcinogenic or mutagenic potential or its potential to impair fertility. There have also been NO animal reproduction studies or studies in pregnant or lactating women and it is not known whether FLUMIST is excreted in human milk..
Hospitalizations and Deaths
An increased rate of hospitalizations (for any cause) through 180 days after final vaccination dose of FLUMIST was observed in children 6-11 months of age.
There were eight deaths reported within 180 days of FLUMIST dosing. Of the 8 deaths, 4 occurred within 42 days after the last dose of FLUMIST. 43 and 180 days after FLUMIST dosing, deaths were due to diarrhea and sepsis, encephalopathy, suffocation, and posterior fossa tumor and malignant hyperthermia.
Full story HERE
No comments:
Post a Comment